Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach

Part of paid clinical trials in Houston, Texas.

Sponsor
The University of Texas Health Science Center, Houston
Study ID
NCT03705715
Phase
PHASE1
Status
Recruiting

Conditions

  • Neuropsychiatric Syndromes

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • PET with radiotracer [11C]PBR-28 ( or [11C]ER176) — DRUG
    \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
  • Affective challenge — OTHER
    Affective challenge is the induction of, for example, mood or affective pain.

Study Details

The purpose of this research is to determine whether there is more extensive inflammation in the brain of people with clinical evidence of neuropsychiatric syndromes, such as mood disorder, chronic pain syndrome, dementia, traumatic brain injury, or substance abuse. The research will also explore whether there is more inflammation in patients with more neuropsychiatric symptoms. Inflammation in the brain will identified by using Positron Emission Tomography (PET) with the radiotracer \[11C\]PBR-28 or \[11C\]ER176.

Key Dates

Start date
May 1, 2017
Status verified
Mar 2025
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: PET with radiotracer [11C]PBR-28 or [11C]ER176
    PET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
  • Experimental: PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge
    PET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.

Primary Outcome Measure

Level of TSPO expression as quantified by PET imaging to detect binding of the TSPO radiotracer [11C]PBR-28 [ Time Frame: obtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
BBSB at UTHealthHoustonTexas77054
alan R Prossin, MBBS
713-486-2836

Find similar trials in Houston, TX